ArticleJournal of traditional and complementary medicine2023
Diabetes mellitus: Preventive and curative therapies with aqueous extract of
Article in Journal of traditional and complementary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antidiabetic activity of the aqueous extract ofMetabolism open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: African traditional healers use Experimental procedure: The induction of T1D was made by intraperitoneal administration of streptozotocin (55 mg/kg b.w). As for T2D, it was induced for 10 days by daily subcutaneous administration of dexamethasone (1 mg/kg b.w). Diabetic animals were divided and treated with AERS (50, 100, and 200 mg/kg b.w) for 28 and 10 days for T1D and T2D, respectively. Glycaemia, food and water consumption, relative body weight, insulinemia, lipid profile, and oxidative stress parameters were evaluated. Histological sections were made on the pancreas of T1D rats. Results and conclusion: AERS (100 and/or 200 mg/kg) prevented (p < 0.05 to p < 0.001) weight loss, polyphagia, and polysipsia in diabetic rats. AERS significantly lowered (p < 0.05 to p < 0.001) insulinemia, hyperglycemia, triglycerides (TG), low-density lipoprotein cholesterol (LDL-c) total cholesterol (TC),and malondialdehyde (MDA). In contrast, a significant increase (p < 0.05 to p < 0.001) in high-density lipoprotein cholesterol (HDL-c) levels, reduced glutathione levels, and superoxide dismutase (SOD) and catalase (CAT) activities were observed with all doses of AERS. Histopathological analysis showed an increase in the number and size of islets of Langerhans in the pancreas of T1D rats receiving AERS. AERS has an important antidiabetic, antidyslipidemic, and antioxidant potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.